Gene Wang, Immetas co-founder and CEO (file photo)

Im­metas Ther­a­peu­tics nabs $11M Se­ries A to nar­row their bis­pe­cif­ic work tar­get­ing in­flam­ma­tion in age-re­lat­ed dis­eases

How does a biotech cel­e­brate its two-year an­niver­sary? For Im­metas Ther­a­peu­tics, it’s with an $11 mil­lion Se­ries A round and a game plan to fight age-re­lat­ed dis­ease.

Co-founders Gene Wang and David Sin­clair came to­geth­er years ago around the idea that in­flam­ma­tion is the ul­ti­mate process dri­ving age-re­lat­ed ill­ness­es, in­clud­ing can­cer. The duo launched Im­metas in 2018 and packed the staff with in­dus­try ex­perts. Wang, who says he’s al­ways had an en­tre­pre­neur­ial spir­it, has held lead roles at No­var­tis, GSK, Bris­tol My­ers Squibb and Mer­ck. He’s worked on block­buster drugs like Hu­mi­ra, Gar­dasil, Varu­bi and Zolin­za. And now, he’s chan­nel­ing that spir­it as CEO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.